Efficient Expression of Naked Plasmid DNA in Mucosal Epithelium: Prospective for the Treatment of Skin Lesions  by Hengge, Ulrich R. et al.
Efficient Expression of Naked Plasmid DNA in Mucosal
Epithelium: Prospective for the Treatment of Skin Lesions
Ulrich R. Hengge, Wolfgang Pfu¨tzner,† Melissa Williams,* Manfred Goos, and Jonathan C. Vogel†
Department of Dermatology and Venerology, University of Essen, Germany; *National Center for Research Resources, Veterinary Resources Program at the
National Institutes of Health (NIH), Bethesda, U.S.A.; †Dermatology Branch, National Cancer Institute, National Institutes of Health, Bethesda, U.S.A.
Mucocutaneous gene therapy offers exciting new treat-
ment modalities for skin lesions. Transient expression
of naked plasmid DNA could be used as a local
treatment of various skin lesions where the correspond-
ing gene product (protein) has therapeutic or immuniza-
tion potential. We analyzed the time course, magnitude,
and histologic expression of the indicator plasmid DNA
(pCMV:b-Gal) in mucosal epithelium and papilloma
lesions. Upon direct injection of naked plasmid DNA
(20 mg) into oral mucosa, expression occurred at high
local concentrations, up to 35-fold higher than in
Gene therapy offers exciting new treatment modalitiesfor skin lesions. The genetic manipulation of epidermiswith the expression of biologic response modifiersrepresents a novel therapeutic approach to treating skinlesions (Vogel, 1993; Hengge, 1997). Recently, we
have demonstrated the ability of epidermal keratinocytes to take up
and transiently express naked (uncoated) plasmid DNA upon direct
intradermal injection, producing high local levels of the corresponding
biologically active protein (Hengge et al, 1995, 1996). This novel
technique could be used as a local treatment of various skin lesions
where the transient production of the appropriate gene product
(protein) has therapeutic potential, and for genetic immunizations.
These entities include Kaposi’s sarcoma, basal cell and squamous cell
carcinoma, and chronic wounds, as well as papilloma (zur Hausen et al,
1991; Phelps, 1995; Stingl et al, 1996; Yang and Huang, 1996).
Expression of immunomodulators such as interferon-α, granulocyte-
macrophage colony-stimulating factor genes, or costimulatory
molecules (e.g., B7.1) at high local levels in the actual tissue might be
advantageous over current treatments (Stingl et al, 1996; Yang and
Huang, 1996). For example, the treatment of HPV-induced papilloma
or condyloma with expression of the therapeutic interferon-α gene
for extended periods of time may be superior to the therapy with
recombinant protein, which is rapidly degraded upon intralesional
injection.
In this study, we show the expression of the indicator plasmid DNA
(pCMV:β-Gal) in mucosal epithelium and papilloma lesions at high
local concentrations upon direct injection. Due to the accelerated
turnover of mucosal epithelium, time course and quantitation experi-
ments were performed in preparation for the design of a study
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comparable injections into the epidermis. Due to
the accelerated turnover of mucosal epithelium b-
galactosidase positive epithelial cells were detected in
the basal and suprabasal layers as early as 3 h after
injection, whereas only the most superficial mucosal
layers demonstrated b-galactosidase staining at 24 h
post-injection. These biologic characteristics need to
be taken into consideration when clinical applications
of expressing naked plasmid DNA in epithelial tissues
are considered. Key words: gene therapy/mucosa/wart.
J Invest Dermatol 111:605–608, 1998
evaluating the therapeutic effects of canine interferon-α plasmid DNA
in the beagle model of oral papillomatosis.
MATERIALS AND METHODS
Plasmid DNA injection Plasmid DNA (pCMV:β-Gal, Clontech, Palo Alto,
CA, containing the β-galactosidase (β-Gal) indicator gene or pcDNA3 vector
control DNA) was injected into the buccal mucosa of 2–4 mo old beagles
or minature swine, which were anesthetized with ketamine, xylazine, butorphan,
and atropine (1:1:1:1). The plasmid DNA was analyzed for β-Gal enzymatic
activity to exclude pseudo-transfection prior to use (Alexander et al, 1997). It
was diluted in phosphate-buffered saline to the concentrations indicated.
Injection was performed into the lamina propria and the papilloma lesion using
a tuberculin syringe and a 30 g needle. The total injected volume was 50 µl.
All plasmid DNA preps were subjected to double cesium chloride purification
and endotoxin levels were monitored using the limulus amebocyte lysate assay
(BioWhittaker, Walkersville, MD), which detects endotoxins chromogenically
(Hurley, 1994; Duner, 1995). When necessary, contaminating endotoxins were
removed from the plasmid DNA using the triton X-114 detergent phase
separation technique (Aida and Pabst, 1990; Cotten et al, 1994). Endotoxin
levels were typically less than 0.005 ng per µg plasmid DNA.
Detection of b-Gal A histochemical staining method was used to detect β-
Gal activity in mucosal specimens as previously described (Hengge et al, 1995).
Briefly, specimens were fixed with paraformaldehyde, washed in phosphate-
buffered saline, and stained with Bluo-Gal staining solution (1 mg per ml in
N-N-dimethylformamide) at room temperature for 4–16 h.
Quantitative assay for b-Gal activity A chemiluminescence assay was
used to quantitate the β-Gal activity in oral mucosa and epidermis (Jain and
Magrath, 1991). Briefly, epithelial, and where appropriate epidermal sheets from
8 mm biopsies were obtained at various times after injection of 20 µg pCMV:β-
Gal into canine mucosa using dispase (10 U per ml for 1 h at 37°C, Boehringer,
Indianapolis, IA) and lyzed in lysis buffer (0.1 M potassium phosphate pH 7.8,
0.2% triton X-100, and 1 mM 1.4-Dithio-DL-threit; Sigma, St. Louis, MO)
using a mortar and pestle. Following centrifugation, a 2 µl aliquot of the cell
extract was mixed with reaction buffer (0.1 M potassium phosphate pH 8.0,
1 mM magnesium chloride, and 0.035 mM Galacton chemiluminescent
substrate, Tropix, Bedford, MA). After a 1 h incubation at room temperature,
10% Emerald luminescence amplifier in 0.2N NaOH (Tropix, Bedford, MA)
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Figure 1. Mucosal epitheliae cells
expressing b-Gal move upward with
time. (a) Gross section of mucosal epithelia
(8 mm punch biopsy) 12 h after injection
of 20 µg of β-Gal plasmid DNA to two
different sites (scale bar: 1 mm); (b) histologic
section of an injected and stained biopsy
3 h after injection of β-Gal plasmid DNA
shows blue staining (β-Gal protein) in basal
and suprabasal layers of the mucosa with
absent staining in the spinous and granular
layers (scale bar: 100 µm); (c) histologic
section of injected mucosa 24 h after β-Gal
plasmid DNA injection demonstrating β-
Gal staining only in the most superficial
mucosal layers (scale bar: 50 µm); (d)
histologic section of porcine epidermis 24 h
after injection showing abundant β-Gal
protein in keratinocytes in all epidermal
layers (scale bar: 50 µm).
was added immediately before measurement of the chemiluminescence in a
chemiluminometer (Monolight 1005, Analytical Luminescence, San Diego,
CA). The β-Gal specific activity in epithelial extracts was calculated as the ratio
of light units divided by the protein content (Biorad, Hercules, CA). Background
β-Gal specific activity in epithelial extracts was determined by injecting non-
β-Gal expressing plasmids (e.g., vector control DNA) with the background
activity being subtracted from positive samples. Assays were performed in
duplicates and compared with a standard curve obtained by spiking β-Gal-
negative cell extracts with known amounts of purified β-Gal (Sigma).
RESULTS
Buccal mucosa expresses b-Gal gene To evaluate the feasibility
of gene therapy in mucosa we determined whether canine buccal
mucosa is capable of taking up and expressing plasmid DNA and then
characterized that expression in terms of histologic localization, time
course, and level of expression. Therefore, 20 µg of β-Gal plasmid
DNA were injected superficially into the buccal mucosa of beagles. β-
Gal was chosen because it can be easily detected in macroscopic and
histologic specimens. Buccal mucosa was found to take up and express
naked plasmid DNA as shown grossly by the intense blue staining of
an 8 mm punch biopsy 12 h after injection (Fig 1a). Histologically,
the level of mucosal keratinocytes expressing β-Gal protein was
analyzed at 3, 6, 12, and 24 h after injection of 20 µg of β-Gal plasmid
DNA. β-Gal protein could be detected as early as 3 h after injection
of β-Gal plasmid DNA in basal and suprabasal layers of the mucosa
with absent staining in the spinous and granular layers (Fig 1b).
Keratinocytes expressing β-Gal plasmid DNA were found in the
spinous and granular layers at 6 and 12 h after injection, whereas β-
Gal protein was not detected in the basal layers at this and later time
points (data not shown). Twenty-four hours after injection, only the
most superficial mucosal layers demonstrated β-Gal staining (Fig 1c)
being consistent with the rapid turnover of mucosal epithelial cells
(Cutright and Bauer, 1967). For comparison, a histologic section of
porcine epidermis is depicted 24 h after injection of β-Gal plasmid
DNA showing abundant β-Gal protein in keratinocytes in all epidermal
layers (Fig 1d). Synthesized β-Gal protein seems to be carried along
within the cells as they migrate upwards and eventually get shed from
the mucosal surface. Uptake and expression of plasmid DNA at later
time points (e.g., 12 h after injection) did not occur because there was
no β-Gal staining in any but the most superficial layers at these later
time points. This might be due to complete uptake of plasmid DNA
following injection or to the instability/degradation of injected plasmid
DNA at the site of injection.
Figure 2. Quantitative time course of b-Gal expression in dog mucosa.
The amounts of β-Gal protein were measured over time in 8 mm epithelial
sheets using a chemiluminescent assay. Six to eight independent samples were
analyzed per time point. Error bars: means 6 SD.
Time course of b-Gal expression in mucosa Quantitatively, the
amounts of β-Gal protein in 8 mm epithelial sheets were measured
over time using a chemiluminescence assay. Consistent with the gross
impression, maximal amounts of β-Gal (3750 ng per 8 mm epithelial
surface) were detected 6 h after the injection of β-Gal with baseline
levels detectable at 48 h after injection (Fig 2).
Amounts of β-Gal protein were compared between trunk skin (pig)
and mucosa (dog) at 12 h after injection of 20 µg of β-Gal plasmid
DNA. Whereas 8 mm epidermal sheets (n 5 10) from (porcine) trunk
skin produced µ100 ng of β-Gal, the same amount of plasmid DNA
led to the synthesis of 3650 ng of β-Gal protein in a 8 mm
epithelial sheet from (canine) buccal mucosa. When this experiment
was performed with β-Gal plasmid injections into porcine mucosa,
comparable high levels of gene product have been obtained (data not
shown). Thus, on a quantitative level it seems that mucosa is able to
produce about 30–35-fold more protein following the injection of β-
Gal plasmid DNA. A potential explanation lies in the different
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Figure 3. Oral papillomas take up and
express intralesionally injected b-Gal
indicator plasmid DNA. Two to four
centimeter papilloma lesions on the gums
of 2–4 mo old beagles were injected with
20 µg β-Gal plasmid DNA. (a) β-Gal
activity could be detected grossly 12 h after
injection (scale bar: 1 mm); (b) on histologic
examination, β-Gal protein was detected
12 h after injection in the most superficial
layers, consistent with the increased
turnover in a hyperproliferative epithelial
lesion (scale bar: 50 µm); (c) gross impression
of pcDNA3 control DNA-injected
papilloma upon analysis for β-Gal activity
(scale bar: 1 mm); (d) histologic evaluation
did not reveal any blue staining (β-Gal
activity) (scale bar: 100 µm).
morphology of buccal mucosa, which has a higher number of ker-
atinocyte layers (10–15) than epidermis, accounting for about 5–8
layers. It is important to remember, however, that β-Gal protein
expression in mucosa has a different time course. Because the turnover
for buccal mucosa is extremely rapid (about 2 d), protein produced
following the uptake of naked plasmid DNA can only be detected for
about 24–48 h, in contrast to epidermally produced protein that was
detectable over a 3 wk period (Hengge et al, 1995).
Canine papilloma express b-Gal Because buccal mucosa did
express the β-Gal marker gene upon injection of β-Gal plasmid DNA,
we wanted to determine whether papilloma lesions also take up and
express naked plasmid DNA. This characteristic would provide the
basis for attempts to treat hyperproliferative epithelial tumors with
plasmid DNA injections encoding cytokines or biologic response
modifiers. To determine this, we injected 20 µg of β-Gal plasmid
DNA into 2–4 cm large oral papillomas on the gums of 2–4 mo old
beagles. β-Gal activity could be detected 12 h after injection (Fig 3a).
On histologic examination, β-Gal activity was detected in the most
superficial layers, consistent with the increased turnover in a hyper-
proliferative epithelial lesion (Fig 3b). At 48 h no β-Gal activity could
be detected (data not shown). For comparison, pcDNA3 control DNA
has been injected and specimens analyzed for β-Gal activity. No blue
staining was seen on macroscopic and histologic examination (Fig 3c–d).
DISCUSSION
The ability of mucosal epithelium to take up and express naked plasmid
DNA at high local concentrations makes it an attractive target for skin
gene therapy. Unlike epidermis, mucosal epithelia have an accelerated
transit time from basal to superficial layers (2–4 d, Cutright and Bauer,
1967), resulting in the early loss of epithelial cells expressing the
introduced DNA as evidenced by the β-Gal gene. Consequently,
mucosa expressed introduced plasmid DNA at all epithelial layers only
very early (3 h) after injection, in contrast to epidermis where
keratinocytes in all layers expressed the introduced gene 24 h after
injection (Hengge et al, 1995). Histologically, β-Gal protein could only
be detected within 48 h after injection, by then the epithelial cells
expressing β-Gal were lost from the mucosal surface. Accordingly, oral
papilloma lesions were shown to take up and express the β-Gal
indicator plasmid with similar time characteristics as mucosa. In order
to detect the produced protein, the following processes need to be
accomplished: transport of DNA from the lamina propria/submucosa
to the basement membrane zone, crossing of the basement membrane,
uptake of DNA by epithelial cells, transport to the nucleus, transcription,
and translation. Therefore, the process of uptake and expression in
epithelial cells seems very rapid and efficient. Given the thickness of
epidermis (5–8 layers) and mucosal epithelium (10–15 layers) and the
fact that a constant amount of plasmid DNA (20 µg) was injected, we
suspect that uptake of plasmid DNA per surface area is substantially
higher in mucosal epithelia than in epidermis. In this regard, projects
are ongoing in order to identify DNA binding proteins in epidermal
and mucosal tissues. On a quantitative level, the efficiency of protein
production in mucosal epithelial cells was found to be significantly
(about 30–35-fold) higher in the first 12 h after injection than in
epidermal keratinocytes. β-Gal protein could not be detected in
epithelial cells later than 48 h after injection due to the loss of the
very cells that have expressed the introduced gene at earlier time
points. Taken together, the quantitative time course of naked plasmid
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DNA expressed in mucosa correlated very well with the histologic
time course. These biologic characteristics need to be taken into
consideration when clinical applications of expressing naked plasmid
DNA in epithelial tissues are considered. In particular, the abundance
of protein products for extended periods of time cannot be achieved
using mucosal tissues; however, the transient expression of certain
biologically relevant proteins at high local quantities may be sufficient
for treatment purposes or the elicitation of an immune response (DNA
vaccination).
This study lays the groundwork for gene therapy approaches using
expression of naked plasmid DNA in epithelium for the treatment of
skin and lesions. Because standard therapies for a variety of skin diseases
such as the treatment of HPV-associated lesions are unsatisfactory, the
injection of naked plasmid DNA encoding biologic response modifiers
like interferon-α might offer a valuable alternative. It remains to be
shown whether plasmid DNA technology is as effective or even
superior to the treatment with recombinant protein.
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